Capital Mãe

计划入组 446 人

CAPITAL OFFLOAD-SHOCK

计划入组 456 人 · 首次发布于 2026 年 8 月 11 日

Park Prescription Trial

计划入组 160 人 · 首次发布于 2015 年 11 月 26 日

ALOS-4 (Ariel University/Roswell Park Cancer Institute)

10-deacetylbaccatin III derivatives

PAD4 inhibitors(Capital Medical University)

University of Lincoln

United Kingdom

Lincoln University College

Malaysia

UNIVERSITY OF NEBRASKA-LINCOLN

United States

Anavex Life Sciences Reports Financial Results and Clinical Advancements in Neurodegenerative Disease Research

Daré Bioscience Fast-Tracks Sildenafil Cream Launch with Dual-Market Strategy for Women's Health

Vaxart Board Battle Intensifies as Independent Directors Urge Shareholders to Back All Six Nominees Ahead of July 16 Annual Meeting